Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer
Lu Huang, Zhi Liao, Zhixi Liu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 11

Showing 11 citing articles:

Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters
Andaleeb Sajid, Hadiar Rahman, Suresh V. Ambudkar
Nature reviews. Cancer (2023) Vol. 23, Iss. 11, pp. 762-779
Closed Access | Times Cited: 78
CRISPR/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders
Bashdar Mahmud Hussen, Zana B. Najmadden, Snur Rasool Abdullah, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 4
Stimulator of Interferon Genes Signal in Lung Cancer Regulates Differentiation of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment Via the Interferon Regulatory Factor 3/NF-κB Pathway
Jiaojiao Ren, Jun Ying, H Liu, et al.
Journal of Interferon & Cytokine Research (2025)
Closed Access
Personalized Approaches to Lung Cancer Treatment: A Review of Targeted Therapies, Pharmacogenomics, and Combination Strategies
M. Tabrizi Namini, G. Bhagya, Manjari Sharma
Aspects of Molecular Medicine (2025), pp. 100073-100073
Open Access
Function of antigen-presenting cells in non-small-cell lung cancer (NSCLC)
Rakesh Kumar, Kamal Jain, Shashi Raj K, et al.
Medical Oncology (2025) Vol. 42, Iss. 5
Closed Access
CRISPR technology: A versatile tool to model, screen, and reverse drug resistance in cancer
Shiva Shirani-Bidabadi, Aliye Tabatabaee, Nazita Tavazohi, et al.
European Journal of Cell Biology (2023) Vol. 102, Iss. 2, pp. 151299-151299
Open Access | Times Cited: 9
Precision in Action: The Role of Clustered Regularly Interspaced Short Palindromic Repeats/Cas in Gene Therapies
Amrutha Banda, Olivia Impomeni, Aparana Singh, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 636-636
Open Access | Times Cited: 3
Nanomaterials-assisted gene editing and synthetic biology for optimizing the treatment of pulmonary diseases
Lanjie Lei, Wenjie Pan, Xin Shou, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
CRISPR technology in human diseases
Qiang Feng, Qirong Li, Hengzong Zhou, et al.
MedComm (2024) Vol. 5, Iss. 8
Open Access | Times Cited: 2
Research into overcoming drug resistance in lung cancer treatment using CRISPR-Cas9 technology: a narrative review
Bin Liu, Ziyu Wang, Meng Gu, et al.
Translational Lung Cancer Research (2024) Vol. 13, Iss. 8, pp. 2067-2081
Open Access | Times Cited: 1
Applications and advancements of CRISPR-Cas in the treatment of lung cancer
Lei Pan, Yixin Ju, Fenfen Peng, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 3
Page 1

Scroll to top